Free Trial

Minerva Neurosciences (NERV) Competitors

Minerva Neurosciences logo
$2.40 +0.03 (+1.43%)
Closing price 08/28/2025 03:50 PM Eastern
Extended Trading
$2.40 0.00 (-0.17%)
As of 08/28/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NERV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Minerva Neurosciences vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and Minerva Neurosciences (NASDAQ:NERV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Minerva NeurosciencesN/AN/A$1.44M$1.481.62

34.6% of Minerva Neurosciences shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Minerva Neurosciences has a consensus target price of $5.00, suggesting a potential upside of 107.99%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Minerva Neurosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.88 beat Minerva Neurosciences' score of 1.87 indicating that 180 Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
180 Life Sciences Very Positive
Minerva Neurosciences Very Positive

180 Life Sciences' return on equity of 0.00% beat Minerva Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Minerva Neurosciences N/A -41.35%31.37%

Summary

Minerva Neurosciences beats 180 Life Sciences on 5 of the 7 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NERV vs. The Competition

MetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.51B$5.78B$9.79B
Dividend YieldN/A1.68%3.95%4.02%
P/E Ratio1.6222.8231.2726.59
Price / SalesN/A550.79435.63155.76
Price / Cash11.34177.0937.7359.36
Price / Book-0.666.1810.966.68
Net Income$1.44M$32.94M$3.27B$265.59M
7 Day Performance-1.07%-0.78%1.44%0.62%
1 Month Performance23.60%2.77%6.24%2.61%
1 Year Performance-14.14%12.01%55.09%22.34%

Minerva Neurosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NERV
Minerva Neurosciences
4.182 of 5 stars
$2.40
+1.4%
$5.00
+108.0%
-13.5%$0.00N/A1.629Positive News
Gap Up
ATNFW
180 Life Sciences
N/A$0.22
+10.1%
N/A+2,713.9%$0.00N/A0.007Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.40
-12.9%
N/AN/A$0.00$110.87K0.0040Gap Up
ALVOW
Alvotech
N/A$1.17
-0.9%
N/A-55.5%$0.00$560.10M0.004
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.03
+6.5%
N/A+139.5%$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.10
-0.1%
N/AN/A$0.00$39.19M0.0070Gap Down
BTMDW
biote
N/A$0.01
-10.6%
N/A-95.8%$0.00$199.07M0.00N/AGap Up
BCTXW
BriaCell Therapeutics
N/A$0.02
-14.8%
N/A-94.3%$0.00N/A0.008Gap Up

Related Companies and Tools


This page (NASDAQ:NERV) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners